Allen Jeffrey, Jahanzeb Mohammad
University of Tennessee Cancer Institute, Memphis, TN 38104, USA.
Clin Lung Cancer. 2008 Sep;9(5):262-70. doi: 10.3816/CLC.2008.n.041.
Extensive-stage small-cell lung cancer (ES-SCLC) is one of the most lethal malignancies, with a median overall survival of only 8-10 months with first-line chemotherapy despite response rates of 60%-80%. In the second-line setting, the prognosis is even more limited, with only 20%-30% of patients having a response and a median survival measured in weeks to months. This article will review systemic chemotherapy in first- and second-line treatment of patients with ES-SCLC and discuss novel therapeutic agents, cytotoxic and "targeted," with an emphasis on recently completed clinical trials and ongoing investigations.
广泛期小细胞肺癌（ES-SCLC）是最致命的恶性肿瘤之一，尽管一线化疗的缓解率为60%-80%，但总体中位生存期仅为8-10个月。在二线治疗中，预后更差，只有20%-30%的患者有反应，中位生存期以数周至数月计。本文将综述ES-SCLC患者一线和二线治疗中的全身化疗，并讨论新型治疗药物，包括细胞毒性药物和“靶向”药物，重点关注近期完成的临床试验和正在进行的研究。
